Literature DB >> 29331941

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.

Célia Gouynou1, Lieven Pouillon1,2, Hélène Rousseau3, Camille Zallot1, Cédric Baumann3, Laurent Peyrin-Biroulet1.   

Abstract

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Pharmacokinetics; Ulcerative colitis; Vedolizumab

Mesh：

Substances：

Year:  2018        PMID： 29331941     DOI： 10.1136/gutjnl-2017-315766

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Authors:  Jurij Hanžel; Nejc Sever; Ivan Ferkolj; Borut Štabuc; Nataša Smrekar; Tina Kurent; Matic Koželj; Gregor Novak; Griet Compernolle; Sophie Tops; Ann Gils; David Drobne
Journal:  United European Gastroenterol J       Date:  2019-03-19       Impact factor: 4.623

2.  Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab.

Authors:  Islam Osama Nassar; Jonathan Cheesbrough; Mohammed Nabil Quraishi; Naveen Sharma
Journal:  Frontline Gastroenterol       Date:  2022-01-24

Review 3.  Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.

Authors:  Lieven Pouillon; Séverine Vermeire; Peter Bossuyt
Journal:  BMC Med       Date:  2019-05-08       Impact factor: 8.775

4.  Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.

Authors:  Mark A Samaan; Siddharth Birdi; Maria Sierra Morales; Sailish Honap; Aravind Gokul Tamilarasan; Georgina Cunningham; Ioannis Koumoutsos; Shuvra Ray; Joel Mawdsley; Simon H C Anderson; Jeremy Sanderson; Peter M Irving
Journal:  Frontline Gastroenterol       Date:  2019-07-11

5.  Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.

Authors:  Renske W M Pauwels; Elisa Proietti; Christien J van der Woude; Lindsey Oudijk; Marie-Rose B S Crombag; Maikel P Peppelenbosch; Ursula Grohmann; Gwenny M Fuhler; Annemarie C de Vries
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.